<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pilot Feasibility Stud</journal-id><journal-id journal-id-type="iso-abbrev">Pilot Feasibility Stud</journal-id><journal-title-group><journal-title>Pilot and Feasibility Studies</journal-title></journal-title-group><issn pub-type="epub">2055-5784</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6149004</article-id><article-id pub-id-type="publisher-id">342</article-id><article-id pub-id-type="doi">10.1186/s40814-018-0342-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Thiamine versus placebo in older heart failure patients: study protocol for a randomized controlled crossover feasibility trial (THIAMINE-HF) </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1759-8603</contrib-id><name><surname>Wong</surname><given-names>Eric Kai Chung</given-names></name><address><email>eric.wong@medportal.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Justin Yusen</given-names></name><address><email>justin.lee@medportal.ca</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Leong</surname><given-names>Darryl P.</given-names></name><address><email>darryl.leong@phri.ca</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mbuagbaw</surname><given-names>Lawrence</given-names></name><address><email>mbuagblc@mcmaster.ca</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Yousuf</surname><given-names>Haroon</given-names></name><address><email>haroon.yousuf@medportal.ca</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Keen</surname><given-names>Sabina</given-names></name><address><email>keens@hhsc.ca</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Straus</surname><given-names>Sharon E.</given-names></name><address><email>sharon.straus@utoronto.ca</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Patterson</surname><given-names>Christopher J.</given-names></name><address><email>pattec@hhsc.ca</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Demers</surname><given-names>Catherine</given-names></name><address><email>demers@hhsc.ca</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution>Division of Geriatric Medicine, Faculty of Medicine, </institution><institution>University of Toronto, St. Michael’s Hospital, </institution></institution-wrap>30 Bond Street, Toronto, Ontario M5B 1W8 Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution>GERAS Centre, Hamilton Health Sciences, </institution><institution>McMaster University, </institution></institution-wrap>88 Maplewood Ave, Hamilton, Ontario L8M 1W9 Canada </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution>Division of Geriatric Medicine, Department of Medicine, </institution><institution>McMaster University, </institution></institution-wrap>88 Maplewood Ave, Hamilton, Ontario L8M 1W9 Canada </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution>Division of Cardiology, Department of Medicine, </institution><institution>McMaster University, </institution></institution-wrap>237 Barton Street E, Hamilton, Ontario L8L 2X2 Canada </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution>Department of Health Research Methods, Evidence, and Impact, </institution><institution>McMaster University, </institution></institution-wrap>50 Charlton Ave. E, Hamilton, Ontario L8N 4A6 Canada </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution>Division of General Internal Medicine, Department of Medicine, </institution><institution>McMaster University, </institution></institution-wrap>50 Charlton Ave. E, Hamilton, Ontario L8N 4A6 Canada </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution>Division of Geriatric Medicine, Department of Medicine, </institution><institution>McMaster University, </institution></institution-wrap>2757 King St. E, Hamilton, Ontario L8G 5E4 Canada </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution>Division of Geriatric Medicine, Faculty of Medicine, </institution><institution>University of Toronto, </institution></institution-wrap>St. Michael’s Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8 Canada </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>9</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>9</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>4</volume><elocation-id>149</elocation-id><history><date date-type="received"><day>22</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>12</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>© The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><text><SENT sid="1" pm="."><plain>Background </plain></SENT>
</text></title><p id="Par1"><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Heart failure (HF) is a major cardiovascular disease with increasing prevalence. </plain></SENT>
<SENT sid="3" pm="."><plain>Thiamine deficiency occurs in 33% of patients with HF. </plain></SENT>
<SENT sid="4" pm="."><plain>However, the effectiveness of thiamine supplementation in HF is not known. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="5" pm="."><plain>Methods </plain></SENT>
</text></title><p id="Par2"><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>In a placebo-controlled randomized two-period crossover feasibility trial, patients age ≥ 60 years with HF and reduced ejection fraction (HFrEF, EF ≤ 45%) will be randomized to thiamine 500 mg oral capsule once daily or placebo for 3 months, then crossed over to the other intervention after a 6-week washout period. </plain></SENT>
<SENT sid="7" pm="."><plain>The primary outcome is recruitment rate. </plain></SENT>
<SENT sid="8" pm="."><plain>Secondary outcomes include feasibility and clinical measures. </plain></SENT>
<SENT sid="9" pm="."><plain>Feasibility outcomes include refusal rate, retention rate, and compliance rate. </plain></SENT>
<SENT sid="10" pm="."><plain>Secondary clinical outcomes include left ventricular ejection fraction, peak global longitudinal strain measured by echocardiography, N-terminal prohormone of brain natriuretic peptide (NT-proBNP), New York Heart Association (NYHA) functional class, Kansas City Cardiomyopathy Questionnaire (KCCQ) quality of life score, and clinical outcomes (all-cause mortality, HF hospitalizations, and HF emergency room visits). </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="11" pm="."><plain>Discussion </plain></SENT>
</text></title><p id="Par3"><SecTag type="ABS"><text><SENT sid="12" pm="."><plain>Thiamine is potentially a safe and low-cost treatment for older patients with HFrEF. </plain></SENT>
<SENT sid="13" pm="."><plain>Results from this study will inform the feasibility of a large clinical trial with clinical endpoints. </plain></SENT>
<SENT sid="14" pm="."><plain>The findings will be published in a peer review journal and presented at a relevant conference. </plain></SENT>
<SENT sid="15" pm="."><plain>This study has received full approval from the Hamilton Integrated Research Ethics Board (18-4537) and Health Canada (210603). </plain></SENT>
<SENT sid="16" pm="."><plain>This trial is funded by the Hamilton Health Sciences New Investigator Grant (15-387) and the McMaster/St. Peter’s Hospital Chair of Aging. </plain></SENT>
</text></SecTag></p></sec><sec><title><text><SENT sid="17" pm="."><plain>Trial registration </plain></SENT>
</text></title><p id="Par4"><SecTag type="ABS"><text><SENT sid="18" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03228030">NCT03228030</ext-link> (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link>), registered July 24, 2017. </plain></SENT>
</text></SecTag></p></sec></abstract><SecTag type="KEYWORD"><kwd-group xml:lang="en"><title>Keywords</title><kwd>Heart failure</kwd><kwd>Thiamine</kwd><kwd>Placebo</kwd><kwd>Crossover</kwd><kwd>Randomized controlled trial</kwd><kwd>Elderly</kwd></kwd-group></SecTag><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008360</institution-id><institution>Hamilton Health Sciences</institution></institution-wrap></funding-source><award-id>15-387</award-id><principal-award-recipient><name><surname>Wong</surname><given-names>Eric Kai Chung</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>McMaster/St. Peter’s Hospital Chair of Aging</institution></funding-source><award-id>N/A</award-id><principal-award-recipient><name><surname>Wong</surname><given-names>Eric Kai Chung</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec id="Sec1"><title><text><SENT sid="19" pm="."><plain>Background </plain></SENT>
</text></title><p id="Par12"><text><SENT sid="20" pm="."><plain>Approximately 500,000 Canadians are living with heart failure (HF), with a prevalence of 1–2% [1]. </plain></SENT>
<SENT sid="21" pm="."><plain>Despite optimal therapy, HF patients experience adverse events, such as hospital admissions and mortality. </plain></SENT>
<SENT sid="22" pm="."><plain>The 1-year mortality for a hospitalized patient with HF is 33% in Canada [2] and readmission rates are nearly 50% within 1 year of hospitalization, increasing with age [3]. </plain></SENT>
<SENT sid="23" pm="."><plain>The total health expenditure related to HF is estimated at $3.9 billion per year in Canada [4]. </plain></SENT>
</text></p><p id="Par13"><text><SENT sid="24" pm="."><plain>A new direction in HF research emphasizes the role of decreased energy production as a mechanism [5]. </plain></SENT>
<SENT sid="25" pm="."><plain>Thiamine, also known as vitamin B1, is an essential micronutrient that is required for energy production in the heart [6]. </plain></SENT>
<SENT sid="26" pm="."><plain>This vitamin is not synthesized in the body, and total body store only amounts to 25–30 mg, which is mostly contained in the skeletal muscles, heart, brain, and kidneys [7]. </plain></SENT>
<SENT sid="27" pm="."><plain>Thiamine is ingested and absorbed in the jejunum and ileum by active transport. </plain></SENT>
<SENT sid="28" pm="."><plain>Once absorbed, free thiamine enters the organs, central nervous system, and erythrocytes. </plain></SENT>
<SENT sid="29" pm="."><plain>Within these tissues and cells, free thiamine is phosphorylated to thiamine pyrophosphate (TPP), which is the biologically active form. </plain></SENT>
<SENT sid="30" pm="."><plain>Thiamine status is quantified by measuring erythrocyte TPP using high-performance liquid chromatography (HPLC) [8]. </plain></SENT>
</text></p><p id="Par14"><text><SENT sid="31" pm="."><plain>Thiamine deficiency is common in patients with HF, with a recent study demonstrating a prevalence of 33% [9]. </plain></SENT>
<SENT sid="32" pm="."><plain>Thiamine plays an important role in cellular energy production, and its deficiency gives rise to both cardiovascular and neurological consequences. </plain></SENT>
<SENT sid="33" pm="."><plain>The clinical syndrome of wet beriberi, which is the result of severe thiamine deficiency, resembles HF, with tachycardia, hypotension, and peripheral edema as presenting findings [10]. </plain></SENT>
<SENT sid="34" pm="."><plain>Heart failure with reduced ejection fraction (HFrEF) is associated with thiamine deficiency in those not taking supplements (49% vs. 24%, p = 0.03) [9]. </plain></SENT>
<SENT sid="35" pm="."><plain>The use of diuretics is also a risk factor for thiamine deficiency, as demonstrated in older studies [11–15]. </plain></SENT>
<SENT sid="36" pm="."><plain>Age also appears to be an important risk factor, with the prevalence of thiamine deficiency increasing with age [16]. </plain></SENT>
<SENT sid="37" pm="."><plain>One study of thiamine deficiency in younger patients with HF (n = 38; mean age = 47) found only one deficiency case [17]. </plain></SENT>
</text></p><p id="Par15"><text><SENT sid="38" pm="."><plain>We propose a randomized placebo-controlled two-period crossover feasibility study of thiamine supplementation in HF. </plain></SENT>
<SENT sid="39" pm="."><plain>This randomized controlled trial (RCT) is warranted because (i) thiamine deficiency is common in this population and appears related to reduced left ventricular ejection fraction (LVEF); causality is uncertain, so an RCT is necessary to ascertain whether the relationship is causal; and (ii) thiamine supplements have a wide therapeutic window, making this intervention safe and widely applicable. </plain></SENT>
<SENT sid="40" pm="."><plain>The aims of the present feasibility study are (i) to determine the feasibility of recruitment for an RCT of thiamine supplementation, (ii) to provide data that will permit refinement of sample size estimates for an RCT that is powered for clinical endpoints, and (iii) to optimize trial procedures with a view to conduct a definitive, larger trial. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="Sec2"><title><text><SENT sid="41" pm="."><plain>Methods </plain></SENT>
</text></title><sec id="Sec3"><title><text><SENT sid="42" pm="."><plain>Design and setting </plain></SENT>
</text></title><p id="Par16"><text><SENT sid="43" pm="."><plain>This is a randomized placebo-controlled two-period crossover feasibility study of thiamine supplementation in HF. </plain></SENT>
<SENT sid="44" pm="."><plain>The study will include symptomatic, stable older patients with decreased LVEF and recent HF hospitalization in the past 12 months. </plain></SENT>
<SENT sid="45" pm="."><plain>The chosen population includes patients who are likely to have thiamine deficiency (older HF patients with decreased LVEF) and likely to respond to therapy. </plain></SENT>
<SENT sid="46" pm="."><plain>Including patients with a recent hospitalization will increase the chances of clinical events, such as recurrent hospitalization or death [18, 19]. </plain></SENT>
<SENT sid="47" pm="."><plain>A two-period crossover design reduces variance between the treatment and control arms. </plain></SENT>
<SENT sid="48" pm="."><plain>We will test the feasibility of recruitment at St. Joseph’s Hospital (SJH), and two sites of the Hamilton Health Sciences Corporation (Juravinski Hospital and Hamilton General Hospital) in Ontario, Canada. </plain></SENT>
<SENT sid="49" pm="."><plain>Eligible patients will be identified on inpatient and outpatient medical units at these sites. </plain></SENT>
<SENT sid="50" pm="."><plain>Subsequent visits will occur at the Hamilton General Hospital. </plain></SENT>
</text></p></sec><sec id="Sec4"><title><text><SENT sid="51" pm="."><plain>Inclusion criteria </plain></SENT>
</text></title><p id="Par17"><text><SENT sid="52" pm="."><plain>Age ≥ 60 years.New York Heart Association (NYHA) class II–IV symptoms.Recent HF-related admission in the past 12 months (defined as HF being reason for admission or HF being a complication during a hospital admission).LVEF ≤ 45% on 2D/3D echocardiography or radionuclide angiography (RNA) in the past 12 months (on optimal therapy).Medically optimized prior to enrolment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (± neprilysin inhibitor), β-blocker, and/or aldosterone antagonist at target or maximally tolerated doses.Stable on medications without hospitalization in the past month. </plain></SENT>
</text></p></sec><sec id="Sec5"><title><text><SENT sid="53" pm="."><plain>Exclusion criteria </plain></SENT>
</text></title><p id="Par24"><text><SENT sid="54" pm="."><plain>Taking &gt; 2.5 mg/day of thiamine supplement.Unable to swallow study medication.Clinical indication for thiamine supplementation including symptomatic thiamine deficiency (Wernicke’s encephalopathy, severe malnutrition, refeeding syndrome) and heavy alcohol use defined as &gt; 15 standard drinks per week in men and &gt; 10 standard drinks per week in women [20].End-stage renal disease on dialysis.Severe mitral valve disease because this impacts the accuracy of speckle tracking analysis on echocardiography [21].Non-English speaking (unable to complete questionnaires).Unable to provide written consent.Cognitive impairment without a caregiver administering medications.Expected survival &lt; 1 year due to non-cardiac disease.Expected heart transplantation in &lt; 6 months (± left ventricular assistive device).Allergies to the ingredients of the study medication or placebo. </plain></SENT>
</text></p></sec><sec id="Sec6"><title><text><SENT sid="55" pm="."><plain>Screening </plain></SENT>
</text></title><p id="Par36"><text><SENT sid="56" pm="."><plain>Eligible patients will be screened by a research nurse in the Heart Function Clinic at Hamilton General Hospital and by physician investigators on medical inpatient and outpatient units at St. Joseph’s Healthcare Hamilton and sites of Hamilton Health Sciences. </plain></SENT>
<SENT sid="57" pm="."><plain>Informed consent will be obtained. </plain></SENT>
<SENT sid="58" pm="."><plain>Older patients with HF often have concomitant cognitive impairment [22]. </plain></SENT>
<SENT sid="59" pm="."><plain>If a diagnosis of cognitive impairment or dementia is documented or known by the patient/informal caregiver (spouse, family member, or friend involved in patient’s health care), then a caregiver must be available to provide medications daily. </plain></SENT>
<SENT sid="60" pm="."><plain>If there is any doubt about a participant’s ability to adhere to study medications or protocols, the study nurse will inform the supervising principal investigator, who will make an assessment. </plain></SENT>
<SENT sid="61" pm="."><plain>Cognitive impairment on its own is not an exclusion criteria as long as there is a reliable way of administering medications (e.g., supervision). </plain></SENT>
<SENT sid="62" pm="."><plain>However, all participants, even those with cognitive impairment, will be required to provide written informed consent independent of the informal caregiver. If the participant, due to cognitive impairment, cannot comprehend sufficiently to provide informed consent, he or she will be excluded from participation. </plain></SENT>
</text></p></sec><sec id="Sec7"><title><text><SENT sid="64" pm="."><plain>Randomization, enrolment, and crossover arrangement </plain></SENT>
</text></title><p id="Par37"><text><SENT sid="65" pm="."><plain>Identical bottles containing either placebo or thiamine will be labeled by the hospital pharmacy using a computer-generated randomization list (allocation concealment). </plain></SENT>
<SENT sid="66" pm="."><plain>Only the pharmacy and our statistician (LM) have access to the randomization list. </plain></SENT>
<SENT sid="67" pm="."><plain>All participants, investigators, and the research nurse will be blinded to group assignments. </plain></SENT>
</text></p><p id="Par38"><text><SENT sid="68" pm="."><plain>Consented patients will be randomized to thiamine or placebo, taken orally once daily for 90 days during the first period. </plain></SENT>
<SENT sid="69" pm="."><plain>The study medication is thiamine mononitrate. </plain></SENT>
<SENT sid="70" pm="."><plain>Capsules in 500 mg dose are produced by the Accurex Health Care Manufacturing Inc. along with identical placebo capsules containing inert filler. </plain></SENT>
<SENT sid="71" pm="."><plain>Participants will be instructed not to take the following foods or health products within 2 h of taking the study medication: areca (betel), horsetail (equisetum), raw freshwater fish, and raw shellfish. </plain></SENT>
<SENT sid="72" pm="."><plain>These foods interfere with thiamine absorption. </plain></SENT>
</text></p><p id="Par39"><text><SENT sid="73" pm="."><plain>Patients will be sequentially assigned to the two groups in a typical AB/BA crossover design [23]. </plain></SENT>
<SENT sid="74" pm="."><plain>The first group (AB) will be given thiamine (treatment A) for 90 days, followed by a 6-week washout period during which no supplements are given. </plain></SENT>
<SENT sid="75" pm="."><plain>The patients will then be given placebo (treatment B) for 90 days. </plain></SENT>
<SENT sid="76" pm="."><plain>The second group (BA) will start with placebo, followed by thiamine. </plain></SENT>
<SENT sid="77" pm="."><plain>Compliance will be tracked by pill counts and thiamine blood test at each clinic visit (0, 3, 4.5, and 7.5 months). </plain></SENT>
<SENT sid="78" pm="."><plain>Patients may continue with concomitant medical care. </plain></SENT>
</text></p></sec><sec id="Sec8"><title><text><SENT sid="79" pm="."><plain>Washout period </plain></SENT>
</text></title><p id="Par40"><text><SENT sid="80" pm="."><plain>The rationale for a 6-week washout period is based on previous studies; the half-life of thiamine is 9–18 days based on a physiology study in young healthy men with radiotagged thiamine [24]. </plain></SENT>
<SENT sid="81" pm="."><plain>Assuming 4–5 half-lives to reach steady-state, drug washout should be completed by 6 weeks. </plain></SENT>
<SENT sid="82" pm="."><plain>Studies in the 1940s of young women showed that a thiamine-deficient diet caused symptoms of deficiency in about 2–3 weeks [25, 26]. </plain></SENT>
<SENT sid="83" pm="."><plain>Our study will not restrict thiamine intake through regular diet, so there is no concern of overt symptomatic thiamine deficiency. </plain></SENT>
<SENT sid="84" pm="."><plain>In HF, there has been one crossover study with thiamine, and a 6-week washout period was used [27]. </plain></SENT>
</text></p></sec><sec id="Sec9"><title><text><SENT sid="85" pm="."><plain>Outcomes </plain></SENT>
</text></title><p id="Par41"><text><SENT sid="86" pm="."><plain>As this is a feasibility study, the primary outcome is recruitment rate with a target to recruit 24 subjects in 11 months for study completion in 18 months. </plain></SENT>
<SENT sid="87" pm="."><plain>The secondary outcomes will include the following feasibility and clinical outcomes. </plain></SENT>
<SENT sid="88" pm="."><plain>Feasibility outcomes include refusal rate (number of eligible patients who refuse to participate), retention rate (number of enrolled patients completing the study), and compliance rate (measured by proportion of participants taking at least 80% of their study medications). </plain></SENT>
</text></p><p id="Par42"><text><SENT sid="89" pm="."><plain>Secondary clinical outcomes include LVEF and peak global longitudinal strain (GLS, %), NT-proBNP, NYHA functional class, quality of life score, and clinical events, which will all be measured at 0, 3, 4.5, and 7.5 months. </plain></SENT>
<SENT sid="90" pm="."><plain>GLS and LVEF will be measured on 2D/3D transthoracic echocardiography. </plain></SENT>
<SENT sid="91" pm="."><plain>The change in GLS and LVEF with supplementation will be used to detect improvement in cardiac function. </plain></SENT>
<SENT sid="92" pm="."><plain>Change in NT-proBNP reflects HF severity and prognosis [28]. </plain></SENT>
<SENT sid="93" pm="."><plain>The change in NYHA functional class will be used to track changes in HF symptoms. </plain></SENT>
<SENT sid="94" pm="."><plain>For quality of life changes, we selected the Kansas City Cardiomyopathy Questionnaire (KCCQ), which is a self-administered disease-specific questionnaire [29]. </plain></SENT>
<SENT sid="95" pm="."><plain>It has been shown to be responsive to change in large HF trials [30]. </plain></SENT>
<SENT sid="96" pm="."><plain>For clinical events, all-cause mortality, HF hospitalizations (hospital stay of ≥ 24 h with confirmed diagnosis of HF using the Boston HF criteria), and HF emergency room (ER) visits (hospital stay &lt; 24 h) will be recorded. </plain></SENT>
</text></p></sec><sec id="Sec10"><title><text><SENT sid="97" pm="."><plain>Data collection </plain></SENT>
</text></title><p id="Par43"><text><SENT sid="98" pm="."><plain>All outcome data will be recorded on paper case report forms (CRF) and stored online using REDCap electronic data capture tools hosted at Hamilton Health Sciences [31]. </plain></SENT>
<SENT sid="99" pm="."><plain>Raw data from 2D/3D echocardiogram machines will be recorded directly into the CRF and secondary echocardiogram variables will be calculated from raw data. </plain></SENT>
<SENT sid="100" pm="."><plain>The NYHA functional class will be determined clinically by an investigator at each visit using the criteria published by the American Heart Association in 1994 [32]. </plain></SENT>
<SENT sid="101" pm="."><plain>The KCCQ is a self-administered disease-specific questionnaire [29]. </plain></SENT>
<SENT sid="102" pm="."><plain>Erythrocyte TPP level will be measured by a local hospital laboratory. </plain></SENT>
<SENT sid="103" pm="."><plain>NT-proBNP will be measured on a point-of-care device by a technician at the Hamilton Health Sciences laboratory. </plain></SENT>
</text></p></sec><sec id="Sec11"><title><text><SENT sid="104" pm="."><plain>Participant timeline </plain></SENT>
</text></title><p id="Par44"><text><SENT sid="105" pm="."><plain>After randomization, patients will attend four study visits: at 0, 3, 4.5, and 7.5 months (Fig. 1). </plain></SENT>
<SENT sid="106" pm="."><plain>Patients will undergo the following tests at the first visit: (i) 2D/3D transthoracic echocardiogram (determine LVEF and GLS) and (ii) blood sampling for baseline NT-proBNP and erythrocyte TPP (approximately 20 ml of blood). </plain></SENT>
<SENT sid="107" pm="."><plain>Patients will be instructed not to take any biotin-containing supplements on the day of bloodwork as these can interfere with NT-proBNP assay [33]. </plain></SENT>
<SENT sid="108" pm="."><plain>Patients will also be asked to complete the KCCQ, followed by an interview with the research nurse for (i) NYHA symptoms, (ii) clinical and medication history, and (iii) physical examination and vital signs. </plain></SENT>
<SENT sid="109" pm="."><plain>Thereafter, patients will be given a 3-month supply of the study drug to take once a day. </plain></SENT>
<SENT sid="110" pm="."><plain>Patients will return to the clinic for reassessment and repeat measurements of the above parameters at 3 months. </plain></SENT>
<SENT sid="111" pm="."><plain>Following a 6-week washout period, patients will attend the 4.5-month visit and the same parameters are measured. </plain></SENT>
<SENT sid="112" pm="."><plain>The patients will take the alternate drug assignment for another 3 months, followed by a final visit at 7.5 months to measure the parameters. </plain></SENT>
<SENT sid="113" pm="."><plain>Deaths, hospitalizations, and ER visits will be recorded at each follow-up. </plain></SENT>
<SENT sid="114" pm="."><plain>The study nurse will look at admission records from local hospitals, including St. Joseph’s Healthcare Hamilton and Hamilton Health Sciences, and ask the patient or caregiver for admissions outside Hamilton. </plain></SENT>
<SENT sid="115" pm="."><plain>Deaths will be determined from local hospital records or by calling the patient’s emergency contact. </plain></SENT>
<SENT sid="116" pm="."><plain>If a patient does not attend follow-up visit, contact will be made via phone or caregiver.Fig. 1Study flow and assessment intervals </plain></SENT>
</text></p></sec><sec id="Sec12"><title><text><SENT sid="117" pm="."><plain>Sample size and recruitment </plain></SENT>
</text></title><p id="Par45"><text><SENT sid="118" pm="."><plain>Using a 95% confidence interval and assuming that 40% of eligible participants will consent to participate in the study, we will need to approach 78 participants in order to recruit 24 (12 per arm). </plain></SENT>
<SENT sid="119" pm="."><plain>This recruitment rate is based on previous experience with other clinical trials conducted at our site with a similar population. </plain></SENT>
<SENT sid="120" pm="."><plain>Twelve participants per arm are sufficiently large to inform the feasibility outcomes of the trial and to provide sufficient precision around effect estimates and their variances [34, 35]. </plain></SENT>
<SENT sid="121" pm="."><plain>Our feasibility trial will be used to inform the following: (i) sample size and power calculations, (ii) expected event rate, (iii) flow of participants, and (iv) dropout rates. </plain></SENT>
<SENT sid="122" pm="."><plain>This study aims to inform a definitive RCT with clinical endpoint of composite of all-cause mortality and HF hospitalizations. </plain></SENT>
</text></p></sec><sec id="Sec13"><title><text><SENT sid="123" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p id="Par46"><text><SENT sid="124" pm="."><plain>The process of patient selection and flow throughout the study will be summarized using a flow-diagram. </plain></SENT>
<SENT sid="125" pm="."><plain>Patient demographics and baseline clinical outcome variables will be summarized using descriptive measures. </plain></SENT>
<SENT sid="126" pm="."><plain>Data will be analyzed based on the intention-to-treat principle, i.e., data for each participant will be analyzed according to allocation irrespective of whether they complied during the treatment period. </plain></SENT>
<SENT sid="127" pm="."><plain>Missing data will be replaced using multiple imputation techniques [31]. </plain></SENT>
<SENT sid="128" pm="."><plain>A secondary per-protocol sensitivity analysis will be conducted for comparison. </plain></SENT>
<SENT sid="129" pm="."><plain>Although our washout period should be sufficient, we will do a pre-test analysis to check for carry-over effects between the groups. </plain></SENT>
<SENT sid="130" pm="."><plain>The primary feasibility outcome is reached when 24 patients are recruited within 11 months. </plain></SENT>
<SENT sid="131" pm="."><plain>Other feasibility thresholds are listed in Table 1. </plain></SENT>
<SENT sid="132" pm="."><plain>Continuous secondary outcome measures will be tested using analysis of covariance (ANCOVA), with outcome measures adjusted for baseline measures and allocation. </plain></SENT>
<SENT sid="133" pm="."><plain>McNemar’s test will be used for categorical outcomes. </plain></SENT>
<SENT sid="134" pm="."><plain>The KCCQ will be analyzed descriptively. </plain></SENT>
<SENT sid="135" pm="."><plain>All tests will be two-sided, meaning that an effect in either direction will be interpreted. </plain></SENT>
<SENT sid="136" pm="."><plain>The level of significance is set at α = 0.05. </plain></SENT>
<SENT sid="137" pm="."><plain>Baseline characteristics and results will be reported as means (standard deviation), medians (interquartile range), counts (percentages), 95% confidence intervals, and levels of statistical significance where appropriate. </plain></SENT>
<SENT sid="138" pm="."><plain>Data will be analyzed using SAS 9.4 (SAS Institute, Cary, NC) and reported according to the CONSORT statement [36].Table 1Outcome measuresOutcome measureScaleTypeMeasureMethod of analysisFeasibility outcomes Enrollment rate per yearRatioContinuousNumber of participants enrolled per yearFeasibility threshold: 24 patients per year Refusal rateRatioContinuousNumber of eligible patients refusing to participateFeasibility threshold: &lt; 40% Retention rateRatioContinuousNumber of participants completing studyFeasibility threshold: &gt; 80% Compliance rateRatioContinuousNumber of participants taking study drug appropriately (≥ 80% study drug)Feasibility threshold: &gt; 90%Clinical outcomes Imaging changesRatioContinuousChange in global longitudinal strain on speckle tracking echocardiography and ejection fractionANCOVA Biomarker changesRatioContinuousChange in NT-proBNPANCOVA Functional changesRatioCategoricalChanges in NYHA classMcNemar’s test Quality of life changesRatioContinuousChanges on the Kansas City Cardiomyopathy QuestionnaireDescriptive All-cause mortalityRatioCategoricalDifference in mortality between groupsMcNemar’s test Heart failure hospitalizationsRatioCategoricalProportion of hospitalizations due to heart failureMcNemar’s test Heart failure-related emergency room visitsRatioCategoricalProportion of ER visits due to heart failureMcNemar’s test </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="Sec14"><title><text><SENT sid="139" pm="."><plain>Discussion </plain></SENT>
</text></title><p id="Par47"><text><SENT sid="140" pm="."><plain>With an aging population, the prevalence of HF is expected to rise with a proportional increase in health care costs. </plain></SENT>
<SENT sid="141" pm="."><plain>Thiamine supplementation is a potentially low-cost and effective intervention to improve cardiac function, particularly in older HF patients with low LVEF. </plain></SENT>
</text></p><p id="Par48"><text><SENT sid="142" pm="."><plain>High-quality RCTs of thiamine supplementation are limited. </plain></SENT>
<SENT sid="143" pm="."><plain>There are only two published placebo-controlled RCTs in patients with stable HF, both of which were small studies. </plain></SENT>
<SENT sid="144" pm="."><plain>Shimon et al. [37] randomized 30 HF patients with LVEF ≤ 45% and taking at least 80 mg/day of furosemide to 7 days of IV thiamine vs. placebo, which resulted in a non-statistically significant improvement in LVEF. </plain></SENT>
<SENT sid="145" pm="."><plain>The use of intravenous thiamine makes the study not easily applicable because this requires either hospitalization or outpatient parenteral therapy, which is not practical. </plain></SENT>
</text></p><p id="Par49"><text><SENT sid="146" pm="."><plain>Schoenenberger et al. [27] completed a two-period randomized crossover study of nine patients with stable HF and LVEF &lt; 40% who were on diuretics to compare oral thiamine 300 mg once daily with placebo for 28 days. </plain></SENT>
<SENT sid="147" pm="."><plain>There was a statistically (but not clinically) significant improvement in LVEF after 28 days of thiamine therapy (LVEF 32.8% vs. 28.8% placebo, p = 0.024). </plain></SENT>
<SENT sid="148" pm="."><plain>Functional outcomes, including a 6-min walk test and dyspnea score, were unchanged. </plain></SENT>
<SENT sid="149" pm="."><plain>Limitations of this study include (i) young age of patients (mean age = 56.7 ± 9.2 years), (ii) short treatment duration, and (iii) not all patients were on optimized guideline-driven HF medications. </plain></SENT>
<SENT sid="150" pm="."><plain>A meta-analysis attempted to pool the results of these two studies and found a significant improvement in LVEF of 3.28% (95% CI 0.64–5.93) for a total of 34 patients [38]. </plain></SENT>
<SENT sid="151" pm="."><plain>This meta-analysis is limited by the quality of the original studies and the small sample size. </plain></SENT>
</text></p><p id="Par50"><text><SENT sid="152" pm="."><plain>This trial builds on prior knowledge by informing the feasibility of conducting a large RCT with clinical endpoints, as well as exploring changes in cardiac function. </plain></SENT>
<SENT sid="153" pm="."><plain>Our study is unique from existing trials because (i) it is designed to inform an RCT powered for clinically important endpoints, (ii) it specifically includes patients likely to reach those endpoints, (iii) it uses an extended treatment period, and (iv) it uses sensitive measures of HF that have prognostic significance. </plain></SENT>
<SENT sid="154" pm="."><plain>Given the low cost of thiamine, high prevalence of HF in our population and possible benefit, this study will guide better HF management with the potential to improve clinical outcomes. </plain></SENT>
</text></p><sec id="Sec15"><title><text><SENT sid="155" pm="."><plain>Trial status </plain></SENT>
</text></title><p id="Par51"><text><SENT sid="156" pm="."><plain>Enrolment begins May 2018. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="ABBR"><glossary><title>Abbreviations</title><def-list><def-item><term>CRF</term><def><p id="Par5">Case report form</p></def></def-item><def-item><term>GLS</term><def><p id="Par6">Peak global longitudinal strain</p></def></def-item><def-item><term>HF</term><def><p id="Par7">Heart failure</p></def></def-item><def-item><term>LVEF</term><def><p id="Par8">Left ventricular ejection fraction</p></def></def-item><def-item><term>NYHA</term><def><p id="Par9">New York Heart Association</p></def></def-item><def-item><term>RCT</term><def><p id="Par10">Randomized controlled trial</p></def></def-item><def-item><term>TPP</term><def><p id="Par11">Thiamine pyrophosphate</p></def></def-item></def-list></glossary></SecTag><SecTag type="ACK_FUND"><ack><title>Acknowledgements</title><p><text4fund><text><SENT sid="157" pm="."><plain>The authors would like to thank members of the New Investigator Fund review committee, the Hamilton Integrated Research Ethics Board, and the University of Toronto Geriatric Medicine Research Review Committee for their helpful recommendations in developing this protocol. </plain></SENT>
</text></text4fund></p><p><text4fund><text><SENT sid="158" pm="."><plain>This study was approved by the Hamilton Integrated Research Ethics Board (2018-4537). </plain></SENT>
<SENT sid="159" pm="."><plain>Written informed consent will be obtained from participants. </plain></SENT>
</text></text4fund></p><sec id="FPar1"><title>Funding</title><p id="Par52"><text4fund><text><SENT sid="160" pm="."><plain>Hamilton Health Sciences New Investigator Fund and McMaster/St. Peter’s Hospital Chair of Aging. </plain></SENT>
<SENT sid="161" pm="."><plain>Study drugs are provided in kind by Accurex Health Care Manufacturing Inc. </plain></SENT>
<SENT sid="162" pm="."><plain>These funding agencies had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results. </plain></SENT>
</text></text4fund></p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par53"><text4fund><text><SENT sid="163" pm="."><plain>The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. </plain></SENT>
</text></text4fund></p></sec></ack></SecTag><notes notes-type="author-contribution"><title>Authors’ contributions</title><p>The study was designed and conceptualized by EW, CD, JL, DL, LM, and CP. The protocol was written by EW, CD, JL, DL, LM, SS, CP, HY, and SK. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar4"><title>Publisher’s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><SecTag type="REF"><ref-list id="Bib1"><title>References</title><ref id="CR1"><text><SENT sid="164" pm="."><plain>1.RossHHowlettJArnoldJMOLiuPO’NeillBJBrophyJMTreating the right patient at the right time: access to heart failure careCan J Cardiol20062274975410.1016/S0828-282X(06)70290-216835668 </plain></SENT>
</text></ref><ref id="CR2"><text><SENT sid="165" pm="."><plain>2.KoDTAlterDAAustinPCYouJJLeeDSQiuFLife expectancy after an index hospitalization for patients with heart failure: a population-based studyAm Heart J200815532433110.1016/j.ahj.2007.08.036<?supplied-pmid 18215604?>18215604 </plain></SENT>
</text></ref><ref id="CR3"><text><SENT sid="166" pm="."><plain>3.JohansenHStraussBArnoldJMOMoeGLiuPOn the rise: the current and projected future burden of congestive heart failure hospitalization in CanadaCan J Cardiol.200319430435<?supplied-pmid 12704491?>12704491 </plain></SENT>
</text></ref><ref id="CR4"><text><SENT sid="167" pm="."><plain>4.CookCColeGAsariaPJabbourRFrancisDPThe annual global economic burden of heart failureInt J Cardiol201417136837610.1016/j.ijcard.2013.12.028<?supplied-pmid 24398230?>24398230 </plain></SENT>
</text></ref><ref id="CR5"><text><SENT sid="168" pm="."><plain>5.NeubauerSThe failing heart--an engine out of fuelN Engl J Med20073561140115110.1056/NEJMra063052<?supplied-pmid 17360992?>17360992 </plain></SENT>
</text></ref><ref id="CR6"><text><SENT sid="169" pm="."><plain>6.GangolfMCzernieckiJRadermeckerMDetryONisolleMJouanCThiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cellsPLoS One20105e1361610.1371/journal.pone.0013616<?supplied-pmid 21049048?>21049048 </plain></SENT>
</text></ref><ref id="CR7"><text><SENT sid="170" pm="."><plain>7.ThomsonADMechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndromeAlcohol Alcohol Suppl2000352710.1093/alcalc/35.Supplement_1.211304071 </plain></SENT>
</text></ref><ref id="CR8"><text><SENT sid="171" pm="."><plain>8.BainesMDaviesGThe evaluation of erythrocyte thiamin diphosphate as an indicator of thiamin status in man, and its comparison with erythrocyte transketolase activity measurementsAnn Clin Biochem198825Pt 669870510.1177/0004563288025006173254112 </plain></SENT>
</text></ref><ref id="CR9"><text><SENT sid="172" pm="."><plain>9.HanninenSADarlingPBSoleMJBarrAKeithMEThe prevalence of thiamin deficiency in hospitalized patients with congestive heart failureJ Am Coll Cardiol20064735436110.1016/j.jacc.2005.08.060<?supplied-pmid 16412860?>16412860 </plain></SENT>
</text></ref><ref id="CR10"><text><SENT sid="173" pm="."><plain>10.BelloSNeriMRiezzoIOthmanMSTurillazziEFineschiVCardiac beriberi: morphological findings in two fatal casesDiagn Pathol20116810.1186/1746-1596-6-8<?supplied-pmid 21244717?>21244717 </plain></SENT>
</text></ref><ref id="CR11"><text><SENT sid="174" pm="."><plain>11.SuterPMHallerJHanyAVetterWDiuretic use: a risk for subclinical thiamine deficiency in elderly patientsJ Nutr Health Aging200046971<?supplied-pmid 10842416?>10842416 </plain></SENT>
</text></ref><ref id="CR12"><text><SENT sid="175" pm="."><plain>12.SicaDomenic A.Loop Diuretic Therapy, Thiamine Balance, and Heart FailureCongestive Heart Failure200713424424710.1111/j.1527-5299.2007.06260.x17673878 </plain></SENT>
</text></ref><ref id="CR13"><text><SENT sid="176" pm="."><plain>13.ZenukCHealeyJDonnellyJVaillancourtRAlmalkiYSmithSThiamine deficiency in congestive heart failure patients receiving long term furosemide therapyCan J Clin Pharmacol200310184188<?supplied-pmid 14712323?>14712323 </plain></SENT>
</text></ref><ref id="CR14"><text><SENT sid="177" pm="."><plain>14.LubetskyAWinaverJSeligmannHOlchovskyDAlmogSHalkinHUrinary thiamine excretion in the rat: effects of furosemide, other diuretics, and volume loadJ Lab Clin Med199913423223710.1016/S0022-2143(99)90202-010482307 </plain></SENT>
</text></ref><ref id="CR15"><text><SENT sid="178" pm="."><plain>15.RieckJHalkinHAlmogSSeligmanHLubetskyAOlchovskyDUrinary loss of thiamine is increased by low doses of furosemide in healthy volunteersJ Lab Clin Med199913423824310.1016/S0022-2143(99)90203-210482308 </plain></SENT>
</text></ref><ref id="CR16"><text><SENT sid="179" pm="."><plain>16.WilkinsonTJHangerHCGeorgePMSainsburyRIs thiamine deficiency in elderly people related to age or co-morbidity?Age Ageing20002911111610.1093/ageing/29.2.11110791444 </plain></SENT>
</text></ref><ref id="CR17"><text><SENT sid="180" pm="."><plain>17.LevyWCSoineLAHuthMMFishbeinDPThiamine deficiency in congestive heart failureAm J Med19929370570610.1016/0002-9343(92)90212-T </plain></SENT>
</text></ref><ref id="CR18"><text><SENT sid="181" pm="."><plain>18.TuppinPCuerqAde PerettiCFagot-CampagnaADanchinNJuillièreYTwo-year outcome of patients after a first hospitalization for heart failure: a national observational studyArch Cardiovasc Dis201410715816810.1016/j.acvd.2014.01.012<?supplied-pmid 24662470?>24662470 </plain></SENT>
</text></ref><ref id="CR19"><text><SENT sid="182" pm="."><plain>19.DharmarajanKHsiehAFKulkarniVTLinZRossJSHorwitzLITrajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort studyBMJ2015h411350 </plain></SENT>
</text></ref><ref id="CR20"><text><SENT sid="183" pm="."><plain>20.Butt P, Beirness D, Gliksman L, Paradis C, Stockwell T. Alcohol and health in Canada: a summary of evidence and guidelines for low-risk drinking. </plain></SENT>
<SENT sid="185" pm="."><plain>Ottawa: Canadian Centre on Substance Abuse; 2011. </plain></SENT>
</text></ref><ref id="CR21"><text><SENT sid="186" pm="."><plain>21.StampehlMRMannDLNguyenJSCotaFColmenaresCDokainishHSpeckle strain echocardiography predicts outcome in patients with heart failure with both depressed and preserved left ventricular ejection fractionEchocardiography2014241639164110.1111/echo.12613 </plain></SENT>
</text></ref><ref id="CR22"><text><SENT sid="187" pm="."><plain>22.LetoLFeolaMCognitive impairment in heart failure patientsJ Geriatr Cardiol20141131632810.11909/j.issn.1671-5411.2014.04.007<?supplied-pmid 25593581?>25593581 </plain></SENT>
</text></ref><ref id="CR23"><text><SENT sid="188" pm="."><plain>23.SibbaldBRobertsCUnderstanding controlled trials. </plain></SENT>
<SENT sid="189" pm="."><plain>Crossover trialsBMJ1998316171910.1136/BMJ.316.7146.1719<?supplied-pmid 9614025?>9614025 </plain></SENT>
</text></ref><ref id="CR24"><text><SENT sid="190" pm="."><plain>24.Ariaey-NejadMRBalaghiMBakerEMSauberlichHEThiamin metabolism in manAm J Clin Nutr19702376477810.1093/ajcn/23.6.7645431041 </plain></SENT>
</text></ref><ref id="CR25"><text><SENT sid="191" pm="."><plain>25.RDWInduced thiamine (vitamin B1) deficiency in manArch Intern Med1943713810.1001/archinte.1943.00210010044003 </plain></SENT>
</text></ref><ref id="CR26"><text><SENT sid="192" pm="."><plain>26.RDWObservations on induced thiamine (vitamin B1) deficiency in manArch Intern Med19406678510.1001/archinte.1940.00190160002001 </plain></SENT>
</text></ref><ref id="CR27"><text><SENT sid="193" pm="."><plain>27.SchoenenbergerAWSchoenenberger-BerzinsRder MaurCASuterPMVergopoulosAErnePThiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot studyClin Res Cardiol201210115916410.1007/s00392-011-0376-2<?supplied-pmid 22057652?>22057652 </plain></SENT>
</text></ref><ref id="CR28"><text><SENT sid="194" pm="."><plain>28.OremusMDon-WauchopeAMcKelvieRSantaguidaPLHillSBalionCBNP and NT-proBNP as prognostic markers in persons with chronic stable heart failureHeart Fail Rev20141947150510.1007/s10741-014-9439-6<?supplied-pmid 24986335?>24986335 </plain></SENT>
</text></ref><ref id="CR29"><text><SENT sid="195" pm="."><plain>29.GreenCPPorterCBBresnahanDRSpertusJADevelopment and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failureJ Am Coll Cardiol2000351245125510.1016/S0735-1097(00)00531-310758967 </plain></SENT>
</text></ref><ref id="CR30"><text><SENT sid="196" pm="."><plain>30.GarinOHerdmanMVilagutGFerrerMRiberaARajmilLAssessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measuresHeart Fail Rev20141935936710.1007/s10741-013-9394-7<?supplied-pmid 23681849?>23681849 </plain></SENT>
</text></ref><ref id="CR31"><text><SENT sid="197" pm="."><plain>31.HarrisPATaylorRThielkeRPayneJGonzalezNCondeJGResearch electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics supportJ Biomed Inform20094237738110.1016/j.jbi.2008.08.01018929686 </plain></SENT>
</text></ref><ref id="CR32"><text><SENT sid="198" pm="."><plain>32.New York Heart AssociationNomenclature and criteria for diagnosis of diseases of the heart and great vessels19949BostonLippincott Williams and Wilkins </plain></SENT>
</text></ref><ref id="CR33"><text><SENT sid="199" pm="."><plain>33.WillemanTCasezOFaurePGauchezASEvaluation of biotin interference on immunoassays: new data for troponin I, digoxin, NT-pro-BNP, and progesteroneClin Chem Lab Med201755e226e22910.1515/cclm-2016-0980<?supplied-pmid 28222017?>28222017 </plain></SENT>
</text></ref><ref id="CR34"><text><SENT sid="200" pm="."><plain>34.JuliousSASample size of 12 per group rule of thumb for a pilot studyPharm Stat2005428729110.1002/pst.185 </plain></SENT>
</text></ref><ref id="CR35"><text><SENT sid="201" pm="."><plain>35.HertzogMAConsiderations in determining sample size for pilot studiesRes Nurs Health20083118019110.1002/nur.20247<?supplied-pmid 18183564?>18183564 </plain></SENT>
</text></ref><ref id="CR36"><text><SENT sid="202" pm="."><plain>36.BeggCChoMEastwoodSHortonRMoherDOlkinIImproving the quality of reporting of randomized controlled trials. </plain></SENT>
<SENT sid="203" pm="."><plain>The CONSORT statementJAMA199627663763910.1001/jama.1996.035400800590308773637 </plain></SENT>
</text></ref><ref id="CR37"><text><SENT sid="204" pm="."><plain>37.ShimonIAlmogSVeredZSeligmannHShefiMPelegEImproved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapyAm J Med19959848549010.1016/S0002-9343(99)80349-07733128 </plain></SENT>
</text></ref><ref id="CR38"><text><SENT sid="205" pm="."><plain>38.DinicolantonioJJLavieCJNiaziAKO’KeefeJHHuTEffects of thiamine on cardiac function in patients with systolic heart failure: systematic review and metaanalysis of randomized, double-blind, placebo-controlled trialsOchsner J201313495499<?supplied-pmid 24357996?>24357996 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
